{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.60","upperLimit":"12.25","value":"10.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Overall survival time is defined as the time from date of registration to the date of death from any cause. Patients discontinuing the study, lost to follow-up or still alive at the end of the study will be censored at the date of last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.\n\nAvelumab: anti-PDL1 antibody","id":"OG000","title":"Avelumab"}],"paramType":"MEDIAN","populationDescription":"Per-protocol population","reportingStatus":"POSTED","timeFrame":"Deaths were collected up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}